Related Experiment Video
Updated: Aug 6, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Staging refinements in renal cell carcinoma
Galen E Howard1, Christopher G Wood
1Department of Urology and Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Current Opinion in Urology
|August 15, 2006
Summary
The 2002 renal cell carcinoma staging system needs refinement. Tumor size and adrenal involvement impact prognosis more than previously thought, suggesting updates are needed for better accuracy.
Area of Science:
- Urology
- Oncology
- Pathology
Background:
- Accurate pathologic staging is crucial for predicting renal cell carcinoma (RCC) outcomes.
- The tumor-node-metastasis (TNM) staging system for RCC has been modified periodically to reflect evolving biological understanding.
- The 2002 TNM staging system modifications have been applied broadly, with ongoing proposals for further refinement.
Purpose of the Study:
- To review recent findings and propose refinements to the current renal cell carcinoma staging system.
- To evaluate the prognostic significance of specific tumor characteristics within the existing staging framework.
- To consider the integration of new data and potential markers for improved prognostic accuracy.
Main Methods:
- Review of recent literature on renal cell carcinoma staging.
- Analysis of prognostic data related to tumor size, invasion, and specific sites.
- Evaluation of the clinical utility and accuracy of current staging criteria.
Main Results:
- The 4 cm breakpoint for T1a/T1b tumors may require re-evaluation, as tumor size shows continuous prognostic significance, particularly between 4-6 cm.
- T3a tumors with adrenal gland involvement exhibit a poor prognosis comparable to T4 tumors.
- Renal sinus invasion may worsen prognosis, while perinephric fat invasion appears less impactful than overall tumor size.
Conclusions:
- Refining the current renal cell carcinoma staging system based on updated tumor characteristic understanding will enhance prognostic accuracy.
- Consideration should be given to incorporating molecular markers and additional features into staging.
- Future staging refinements must balance improved accuracy with clinical usability and avoid excessive complexity.
